Evaluation of the immune potentiating effect of the NAcGM3/VSSP/Montanide ISA 51 formulation in HIV patients, phase II.
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2017
At a glance
- Drugs N-acetyl GM3 vaccine (Primary) ; Montanide ISA-51
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- 23 Sep 2011 New trial record